NouvSight001 / iRegene Therap - LARVOL DELTA

iRegene Therapeutics…announced that its investigational cell therapy NouvSight001 has received clearance from China's National Medical Products Administration (NMPA) for a Phase I/III clinical trial in patients with retinitis pigmentosa (RP) to evaluate its safety, tolerability and preliminary efficacy (PRNewswire) - "The U.S. Food and Drug Administration (FDA) has also cleared NouvSight001 for a Phase I/II clinical trial for the same indication and granted a special exemption."

IND • New trial • Ophthalmology • Retinal Disorders